Carregando empresa
Just reported
Q1 FY2027 results
From Phibro Animal Health's results release of 4 de novembro de 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 386,8M
+6,3% y/y
-2,5% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$ 0,72
+11% y/y
+36% q/qGuided
—
No guide given
EPS, adjusted: US$ 0,79
Operating income, GAAP
Actual
US$ 49,6M
-3,2% y/y
+3,1% q/qGuided
—
No guide given
Company outlook
Q1 FY2027
- RevenueUS$ 386,8M+6,3% y/y First given
- EPS, adjustedUS$ 0,79First given
- EPSUS$ 0,72First given
Full year 2027
- RevenueUS$ 1,55B – US$ 1,6B+3,7% y/y Unchanged
- EPS, adjustedUS$ 3,41 – US$ 3,59Unchanged
- EPSUS$ 2,98 – US$ 3,22Unchanged
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Phibro Animal Health is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company LimitedUS$ 34,4BA
NBIXNeurocrine Biosciences, Inc.US$ 16,9BA+
ELANElanco Animal Health IncorporatedUS$ 13,4BA
KNSAKiniksa Pharmaceuticals International, plcUS$ 8,2BA+
LQDALiquidia CorporationUS$ 5,2BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 de nov. de 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 de out. de 2026CAGraded C, now A
Demonstrações financeiras completas →
Construído a partir dos próprios documentos de Phibro Animal Health Corporation entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
